Compare · SPEC vs TMO
SPEC vs TMO
Side-by-side comparison of Spectaire Holdings Inc. (SPEC) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SPEC and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO carries a market cap of $225.41B.
- TMO has hit the wire 6 times in the past 4 weeks while SPEC has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for SPEC).
- Company
- Spectaire Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.17-36.05%
- $469.57+0.63%
- Market cap
- -
- $225.41B
- 1M return
- -
- -4.31%
- 1Y return
- -
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest SPEC
- Spectaire Holdings Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- Spectaire Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Amendment: SEC Form SC 13G/A filed by Spectaire Holdings Inc.
- Spectaire Holdings Inc. filed SEC Form 8-K: Leadership Update
- Spectaire Holdings Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- SEC Form 25-NSE filed by Spectaire Holdings Inc.
- SEC Form NT 10-Q filed by Spectaire Holdings Inc.
- Spectaire Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Spectaire Completes First Ever Carbon Credit Transaction Sourced from Measured1 Diesel Engine Emissions and Takes Carbon Credit Trading Platform AireCoreX Live; Announces NASDAQ Hearing Results
- Spectaire Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S